The clinical study to explore the effecs of anagliptin on responses of plasma glucose and lipid in new-onset type 2 diabetic patients

The clinical study to explore the effecs of anagliptin on responses of plasma glucose and lipid in new-onset type 2 diabetic patients - The clinical study to explore the effecs of anagliptin on responses of plasma glucose and lipid in new-onset type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014170

Enrollment

Registered

2014-06-07

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

New-onset Type 2 Diabetes

Interventions

Anagliptin 100 mg twice a day 24weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. HbA1c >= 6.5 % 2. LDL-c >= 120 mg/dL

Exclusion criteria

Exclusion criteria: 1.Patients who take other oral hypoglycemic agent 2.Patients who are past history of hypersensitivity to anagliptin 3.Patients who are severe ketosis or diabetic coma, precoma, type 1 diabetes 4.Patients who are severe infection or perioperative, severe injury 5.Pregnant or woman of child-bearing potential 6.Patients who are severe renal dysfunction or dialysis ESRD 7.Patients who are severe hepatic dysfunction 8.Patients who are judged as inappropriate for inclusion by phsicians

Design outcomes

Primary

Measure	Time frame
ApoB48(MTT), LDL-c(MTT), plasma glucose(MTT), HbA1c	—

Secondary

Measure	Time frame
TC(MTT), TG(MTT), HDL-c(MTT), non-HDL-c(MTT), Body weight, Blood presure, biochemical test, general blood test etc.	—

Countries

Japan

Contacts

Public ContactOsamu Tomonaga

Tomonaga Clinic Diabetes And Lifestyle Center

boss@tomonaga-clinic.com03-3351-0032

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026